Patients (N) | 202 |
Age (LRP year) | Â |
 Median (IQR*) | 67.0 (64–71) |
PSA level (ng/mL) | Â |
 Median (IQR) | 9.4 (7.3–13.5) |
Prostate Weight (mL) | Â |
 Median (IQR) | 60.0 (47.1–78.5) |
PSAD (ng/mL2) | Â |
 Median (IQR) | 0.2 (0.2–0.1) |
 Gleason score | n (%) |
 3 + 3 | 7 (3.0) |
 3 + 4 | 101 (48.0) |
 4 + 3 | 35 (17.0) |
 3 + 5 | 21 (10.0) |
 4 + 4 | 3 (1.0) |
 4 + 5 or more | 45 (21.0) |
 pT stage | n (%) |
 pT2a | 11 (5.0) |
 pT2b | 3 (1.0) |
 pT2c | 106 (50.0) |
 pT3a | 67 (32.0) |
 pT3b | 23 (11.0) |
 pT4 | 2 (1.0) |
 Lymph node status | n (%) |
 pN0 | 187 (88.0) |
 pN1 | 13 (6.0) |
 pNX | 12 (6.0) |
 PIRADS | n (%) |
 3 | 16 (7.6) |
 4 | 59 (27.8) |
 5 | 137 (64.6) |